Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epratuzumab - Immunomedics

Next Previous
X
Search
Drug Profile

Epratuzumab - Immunomedics

Alternative Names: AMG 412; Epratucyn; hCD22; Humanised monoclonal antibody LL2; Humanized anti-CD22 monoclonal antibody IgG1; IMMU 103; IMMU LL2; LymphoCide

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunomedics
  • Developer Charite - Universitatsmedizin Berlin; Children's Oncology Group; Immunomedics; National Cancer Institute (USA); UCB
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase II Non-Hodgkin's lymphoma
  • Discontinued Cachexia; Systemic lupus erythematosus

Most Recent Events

  • 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
  • 08 Jan 2020 Discontinued - Phase-I/II for Precursor cell lymphoblastic leukaemia-lymphoma (Combination therapy, In adolescents, In children, Second-line therapy or greater, In adults) in Canada, Puerto Rico (IV)
  • 08 Jan 2020 Discontinued - Phase-I/II for Precursor cell lymphoblastic leukaemia-lymphoma (Combination therapy, Second-line therapy or greater, In adults) in Australia (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top